DekaBank Deutsche Girozentrale Has $1.74 Million Position in Teleflex Incorporated (NYSE:TFX)

DekaBank Deutsche Girozentrale lowered its holdings in shares of Teleflex Incorporated (NYSE:TFX) by 56.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,110 shares of the medical technology company’s stock after selling 9,137 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Teleflex were worth $1,744,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. International Assets Investment Management LLC boosted its stake in Teleflex by 20,300.0% during the fourth quarter. International Assets Investment Management LLC now owns 2,244 shares of the medical technology company’s stock worth $560,000 after buying an additional 2,233 shares in the last quarter. Boston Trust Walden Corp boosted its stake in shares of Teleflex by 17.6% in the 4th quarter. Boston Trust Walden Corp now owns 227,888 shares of the medical technology company’s stock valued at $56,822,000 after purchasing an additional 34,100 shares in the last quarter. Arizona State Retirement System boosted its stake in shares of Teleflex by 0.8% in the 4th quarter. Arizona State Retirement System now owns 12,915 shares of the medical technology company’s stock valued at $3,220,000 after purchasing an additional 100 shares in the last quarter. Venturi Wealth Management LLC boosted its stake in shares of Teleflex by 33.3% in the 4th quarter. Venturi Wealth Management LLC now owns 184 shares of the medical technology company’s stock valued at $46,000 after purchasing an additional 46 shares in the last quarter. Finally, Oak Thistle LLC acquired a new stake in shares of Teleflex in the 4th quarter valued at $386,000. Institutional investors and hedge funds own 95.62% of the company’s stock.

Teleflex Stock Performance

Shares of NYSE:TFX opened at $214.44 on Friday. The stock has a market capitalization of $10.10 billion, a P/E ratio of 28.48, a P/E/G ratio of 2.05 and a beta of 1.11. Teleflex Incorporated has a 1-year low of $177.63 and a 1-year high of $276.43. The company has a current ratio of 2.32, a quick ratio of 1.29 and a debt-to-equity ratio of 0.39. The business has a 50-day moving average price of $229.64 and a two-hundred day moving average price of $224.94.

Teleflex (NYSE:TFX) last announced its quarterly earnings results on Thursday, February 22nd. The medical technology company reported $3.38 EPS for the quarter, beating analysts’ consensus estimates of $3.26 by $0.12. The company had revenue of $773.90 million during the quarter, compared to analysts’ expectations of $769.01 million. Teleflex had a return on equity of 14.98% and a net margin of 11.98%. Teleflex’s revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the business posted $3.52 EPS. Equities analysts predict that Teleflex Incorporated will post 13.73 earnings per share for the current year.

Teleflex Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 15th. Stockholders of record on Friday, March 1st were paid a $0.34 dividend. The ex-dividend date of this dividend was Thursday, February 29th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.63%. Teleflex’s dividend payout ratio (DPR) is presently 18.06%.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on TFX shares. Raymond James boosted their target price on shares of Teleflex from $227.00 to $271.00 and gave the company an “outperform” rating in a research note on Wednesday, December 20th. Truist Financial reduced their target price on shares of Teleflex from $270.00 to $265.00 and set a “hold” rating on the stock in a research note on Friday, February 23rd. Royal Bank of Canada cut their price target on Teleflex from $272.00 to $265.00 and set an “outperform” rating for the company in a report on Friday, February 23rd. JMP Securities reaffirmed a “market outperform” rating and issued a $285.00 price target on shares of Teleflex in a report on Friday, February 23rd. Finally, StockNews.com cut Teleflex from a “buy” rating to a “hold” rating in a report on Friday, February 23rd. Five analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $265.56.

Insider Activity

In other news, VP Cameron P. Hicks sold 7,401 shares of the company’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $225.00, for a total value of $1,665,225.00. Following the completion of the sale, the vice president now directly owns 10,050 shares of the company’s stock, valued at approximately $2,261,250. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.41% of the stock is currently owned by company insiders.

Teleflex Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.